Dasiglucagon Shows Promise in Mitigating Hypoglycemia after bariatric surgery

Conducted at the Center for Clinical Metabolic Research at Gentofte Hospital in Denmark, the study employed a randomized, double-blind, placebo-controlled, crossover, proof-of-concept approach. Twenty-four individuals, predominantly women, with verified postbariatric hypoglycemia were assigned to two treatment periods involving 4 weeks of self-administered subcutaneous dasiglucagon at 120 μg or a placebo. The primary outcomes were measured through continuous glucose monitoring, focusing on the percentage of time spent in level 1 and 2 hypoglycemia.

The key findings of the study were:

• Dasiglucagon showcased remarkable efficacy compared to the placebo, reducing time spent in level 1 hypoglycemia by 33% and level 2 hypoglycemia by 54%.

• Notably, dasiglucagon rapidly corrected hypoglycemia within 15 minutes in a significant majority of cases, outperforming the placebo by a substantial margin.

• The treatment was generally well-tolerated, with mild to moderate adverse events, primarily nausea.

The study concludes that dasiglucagon, when self-administered over a 4-week period, effectively reduces clinically relevant hypoglycemia in individuals who have undergone Roux-en-Y gastric bypass surgery. This breakthrough suggests a potential avenue for managing postbariatric hypoglycemia, offering hope for improved treatment options in the future.

Reference:

Nielsen, C. K., Øhrstrøm, C. C., Houji, I. J. K., Helsted, M. M., Krogh, L. S. L., Johansen, N. J., Hartmann, B., Holst, J. J., Vilsbøll, T., & Knop, F. K. Dasiglucagon treatment for postprandial hypoglycemia after gastric bypass: A randomized, double-blind, placebo-controlled trial. Diabetes Care,2023;46(12):2208–2217. https://doi.org/10.2337/dc23-1193